The anti-flu drug favipiravir (brand name Avigan) from Japan reportedly showed promising results in treating coronavirus patients at recent clinical trials.
DOH experts studying use of flu drug for COVID
Sheila Crisostomo (The Philippine Star) - March 31, 2020 - 12:00am

MANILA, Philippines — Health Secretary Francisco Duque III has directed a group of experts to look into a Japanese anti-flu medicine that shows potential in fighting coronavirus disease 2019 (COVID-19).

Duque has asked the technical advisory group of the Department of Health to study the developments related to the anti-flu drug favipiravir (brand name Avigan), which reportedly showed promising results in two recent clinical trials.

The anti-flu medication was seen effective against SARS-CoV-2, the virus that causes COVID-19.

“The technical advisory group is studying it now and they will make recommendations whether or not it can be used in our hospitals here,” he said yesterday.

Food and Drug Administration (FDA) director general Eric Domingo said the drug is not yet produced commercially, but they are planning to make representations to bring it to the Philippines in case it gets approved for use for COVID-19 patients.

  • Latest
  • Trending
Are you sure you want to log out?
Login is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

or sign in with